CVS (CVS) Offering Possible 31.93% Return Over the Next 31 Calendar Days

CVS's most recent trend suggests a bullish bias. One trading opportunity on CVS is a Bull Put Spread using a strike $72.50 short put and a strike $67.50 long put offers a potential 31.93% return on risk over the next 31 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $72.50 by expiration. The full premium credit of $1.21 would be kept by the premium seller. The risk of $3.79 would be incurred if the stock dropped below the $67.50 long put strike price.

The 5-day moving average is moving up which suggests that the short-term momentum for CVS is bullish and the probability of a rise in share price is higher if the stock starts trending.

The 20-day moving average is moving up which suggests that the medium-term momentum for CVS is bullish.

The RSI indicator is above 80 which suggests that the stock is in overbought territory.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here

LATEST NEWS for CVS

Is It Smart To Buy CVS Health Corporation (NYSE:CVS) Before It Goes Ex-Dividend?
Sun, 17 Jan 2021 06:13:49 +0000
Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be…

FOCUS-Some U.S. nursing home residents face delays for COVID-19 vaccines despite extreme risk
Fri, 15 Jan 2021 18:30:11 +0000
A former Arkansas health official is sounding alarms about the pace of coronavirus vaccines being administered to residents of long-term care facilities under a U.S. plan that puts major pharmacy chains CVS and Walgreens in charge of many of the shots. Fewer than 10% of doses allocated to those Arkansas seniors have been administered, according to the state health department. The two pharmacies are working with about 40% of the state's facilities.

Best Healthcare Stocks to Buy for 2021
Fri, 15 Jan 2021 13:27:00 +0000
Real Money contributor Stephen Guilfoyle checks which sector names could perform best over the coming year.

West Virginia is vaccinating people faster than California — here’s why
Fri, 15 Jan 2021 13:22:00 +0000
One key to unlocking the logjam of COVID-19 vaccines is in plain view but so far overlooked: the neighborhood retail pharmacy. As of Monday,  9 million people had received at least one dose of the Pfizer (PFE) or Moderna (MRNA) vaccines since they were approved in December. Pfizer’s vaccine must be stored at minus 70 degrees Celsius which complicates inoculation efforts that are not close to specialty freezers.

FOCUS-Some big U.S. pharmacies will not check ID before administering COVID-19 vaccines
Fri, 15 Jan 2021 11:00:00 +0000
Many U.S. pharmacies, including those inside Kroger Co supermarkets and the drugstore chain of CVS Health Corp, say they will not be checking IDs before administering COVID-19 vaccines, leaving the door open to those who do not meet states' guidelines to jump the line. While the United States has distributed more than 30 million vaccine doses, a little over 11 million had been administered as of Thursday, a lag that prompted U.S. health secretary Alex Azar to call on states to begin vaccinating the vulnerable older population and those with certain chronic health conditions to get more vaccines into arms. U.S. retailers face a choice of strictly enforcing state eligibility rules with on-site identity checks, or rely on an honor system that could allow people to ignore those guidelines but also get more people inoculated.

Related Posts

 

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.


This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.


The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.


The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.